双重向的宏分子:双特异性抗体作为下一代类型的治疗方法,用于类风湿性关节炎
Ali Afshari1, Jafar Karami2, Mitra Abbasifard3
1Department of Internal Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
International journal of biological macromolecules
|August 17, 2025
概括
双特异性抗体 (BsAbs) 通过向多个免疫路径,为风湿性关节炎 (RA) 治疗提供了一种新的方法. 需要进一步的研究来应对挑战,并优化BsAbs以改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 生物技术是生物技术.
背景情况:
- 类风湿性关节炎 (RA) 涉及复杂的免疫失调.
- 目前的RA疗法,包括单一疗法,都有局限性.
- 双特异性抗体 (BsAbs) 代表了RA的新疗法策略.
研究的目的:
- 批判性地审查RA中BsAbs的临床前和临床研究结果.
- 要突出目前的研究发展在BsAbs的RA.
- 提出克服BsAbs在RA中的翻译障碍的策略.
主要方法:
- 对RA的BsAbs现有临床前研究的审查.
- 对RA中BsAbs的早期临床试验数据的分析.
- 讨论与BsAbs.相关的抗体工程进展.
主要成果:
- 在早期研究中,BsAbs显示出有前途的效率和安全性.
- 关于BsAbs的稳定性,药理动力学和免疫性,仍然存在挑战.
- 生物标志物的精细化对于预测治疗反应和患者选择至关重要.
结论:
- 通过同时针对多个途径,BsAbs提供了增强RA管理的潜力.
- 为了优化BsAbs,需要对细胞因子网络和细胞动态进行进一步的研究.
- 需要采取战略方法,以促进BsAbs在RA的临床转化.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Cross-reactivity
31.5K
Overview
31.5K
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Genome-wide Association Studies-GWAS
14.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.2K


